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Aims More than 50% of patients with heart failure have preserved ejection fraction characterized by diastolic dysfunction.
The prevalance of diastolic dysfunction is higher in females and associates with multiple comorbidities such as
hypertension (HT), obesity, hypercholesterolemia (HC), and diabetes mellitus (DM). Although its pathophysiology
remains incompletely understood, it has been proposed that these comorbidities induce systemic inflammation,
coronary microvascular dysfunction, and oxidative stress, leading to myocardial fibrosis, myocyte stiffening and, ul-
timately, diastolic dysfunction. Here, we tested this hypothesis in a swine model chronically exposed to three com-
mon comorbidities.
....................................................................................................................................................................................................
Methods
and results
DM (induced by streptozotocin), HC (produced by high fat diet), and HT (resulting from renal artery embolization),
were produced in 10 female swine, which were followed for 6 months. Eight female healthy swine on normal pig-
chow served as controls. The DMþHCþHT group showed hyperglycemia, HC, hypertriglyceridemia, renal dys-
function and HT, which were associated with systemic inflammation. Myocardial superoxide production was mark-
edly increased, due to increased NOX activity and eNOS uncoupling, and associated with reduced NO production,
and impaired coronary small artery endothelium-dependent vasodilation. These abnormalities were accompanied
by increased myocardial collagen content, reduced capillary/fiber ratio, and elevated passive cardiomyocyte stiffness,
resulting in an increased left ventricular end-diastolic stiffness (measured by pressure–volume catheter) and a trend
towards a reduced E/A ratio (measured by cardiac MRI), while ejection fraction was maintained.
....................................................................................................................................................................................................
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Conclusions The combination of three common comorbidities leads to systemic inflammation, myocardial oxidative stress, and
coronary microvascular dysfunction, which associate with myocardial stiffening and LV diastolic dysfunction with
preserved ejection fraction.
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1. Introduction
More than 50% of patients with heart failure present with heart failure
with preserved ejection fraction (HFpEF), characterized by diastolic dys-
function.1 Hospitalized patients with HFpEF have high mortality and
rehospitalization rates, and there is currently no effective treatment
available for these patients.2–4 Common metabolic and cardiovascular
risk factors appear to be critical in the onset of diastolic dysfunction and
its progression towards HFpEF, as the incidence of HFpEF increases with
rising prevalence of obesity, hypertension (HT), chronic kidney disease,
female sex, and type 2 diabetes mellitus (DM).5–7 Furthermore, studies
in HFpEF patients have shown alterations in myocardial structure, func-
tion, and cell signaling that are unique to this form of heart failure.8–11
However, the pathophysiology of HFpEF is still not fully understood, par-
ticularly at the myocardial tissue level. Findings from these earlier studies
have led to the proposition of a novel paradigm, in which multiple
comorbidities, including obesity, HT, hypercholesterolemia (HC), and
DM induce a systemic pro-inflammatory state that leads to coronary
microvascular dysfunction and oxidative stress. In turn, these disease
mechanisms result in myocardial stiffening and ultimately left ventricular
diastolic dysfunction.12 Nevertheless, direct experimental evidence for
this unifying hypothesis is still lacking. We set out to investigate the chain
of events as proposed in this novel paradigm, using a large animal model
chronically exposed to three common comorbidities that associate with
diastolic dysfunction, i.e. hyperglycemia, HC, and HT. Since the preva-
lence of this disease is predicted to increase in our aging Western soci-
eties,13 such unique large animal model that mimics the complex disease
mechanisms of diastolic dysfunction would offer a much needed plat-
form for testing novel drug and lifestyle therapies.
2. Methods
2.1 Animals
Experiments were performed in accordance with the ‘Guiding Principles
in the Care and Use of Laboratory Animals’ as approved by the Council
of the American Physiological Society, and with approval of the Animal
Care Committee at Erasmus University Medical Center, Rotterdam.
Fourteen female (21.7± 0.3 kg at 2–3 months of age) Yorkshire x
Landrace swine were included to study the effects of DM, HC, and HT
(DMþHCþHT), while 12 healthy female swine of similar age were
studied as controls (Control). Finally, six fresh control hearts from
slaughterhouse female swine of similar body weight as the control ani-
mals (100 kg at sacrifice) were included to additionally study vascular
function characteristics.
2.2 Induction of risk factors
The induction of risk factors in the DMþHCþHT group is described
in detail in the Supplementary material online, Supplementary Methods.
Briefly, DM was produced by injection of streptozotocin (50 mg/kg/day
i.v. for 3 days, Bio-connect B. V., Huissen, The Netherlands). 9- to
11 days later, animals were sedated with intramuscular Zoletil (tilet-
amine/zolazepam; 5 mg/kg), Rompun (xylazine; 2.25 mg/kg) and atropine
(1 mg), and artificially ventilated (O2 and N2 [1:2]), to which 1–2% (vol/
vol) isoflurane was added. HT was produced by micro-embolization of
the global right kidney as well as the lower pole of the left kidney using
75 mg of polyethylene microspheres (38–42lm diameter, Cospheric,
Santa Barbara, CA, USA) per kidney. One week after HT induction, a
high fat diet (see Supplementary material online, Table S1), supplemented
with 10 g NaCl/day was gradually introduced to produce HC.
2.3 Hemodynamic assessment
At 6 months follow-up, extensive in vivo hemodynamic assesment was
performed with the animals under anesthesia (pentobarbital, 20 mg/kg
i.v.) and in the awake state. All procedures are described in detail in the
Supplementary material online, Supplementary Methods. Briefly, LV func-
tion was assessed using MRI (Discovery MR450, GE Medical System,
Milwaukee, Wisconsin, USA), including end-diastolic volume (EDV),
end-systolic volume (ESV), E/A ratio, stroke volume (SV), and ejection
fraction (EF), and using a pressure–volume catheter (CD Leycom, The
Netherlands), including EDV, ESV, SV, EF, end-diastolic (EDPVR), and
end-systolic (ESPVR) pressure–volume relationships. Eight animals
(4 DMþHCþHT, and 4 Control) were instrumented between 5- and
6-month follow-up with a Transonic flow probe around the ascending
aorta and fluid filled catheters in the left atrium and aorta for hemo-
dynamic measurements at rest and during exercise and the evaluation of
kidney function.
2.4 Coronary small artery function in vitro
In order to assess coronary vascular endothelial function, coronary small
arteries (300mm diameter) were isolated from the epicardial surface
of the LV apex and studied in vitro using a Mulvany wire myograph as pre-
sented in the Supplementary material online, Supplementary Methods. In
short, the concentration–response curves (CRC) were measured for
the endothelium-dependent vasodilator bradykinin (BK, 10-10 to
10-6 mol/l, Sigma–Aldrich, Zwijndrecht, The Netherlands) and the ex-
ogenous NO-donor, S-nitroso-N-acetylpenicillamine (SNAP, 10-10 to
10-5 mol/l, Sigma–Aldrich, Zwijndrecht, The Netherlands) following pre-
constriction with 10-6mol/l thromboxane-A2 analogue U46619 (Sigma–
Aldrich, Zwijndrecht, The Netherlands).
2.5 Tissue analysis
All analyses are described in detail in the Supplementary material online,
Supplementary Methods. Briefly, snap frozen samples of the subendocar-
dium of the LV anterior free wall were analysed for mRNA expression
levels of various genes (see Supplementary material online,
Supplementary Methods Table S2), involved in different phases of develop-
ment of diastolic dysfunction, reactive oxygen species (ROS), and NO
production for NO-ROS balance, eNOS expression, and
phosphorylation in order to asess eNOS uncoupling and activity.
Myocardial levels of cyclic guanosine monophosphate (cGMP), and
activity of phosphodiesterase 5 (PDE5) and protein kinase G (PKG)
Comorbidities in swine result in diastolic dysfunction 955
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were measured using ELISA kits, to assess alterations in the downstream
signalling pathway of NO. Calcium-force relations of single cardiomyo-
cytes were performed for cardiomyocyte stiffness measurements. In
addition, titin isoform- (N2BA and N2B) expression and phosphoryl-
ation were measured as previously described.14 Furthermore, histolo-
gical analyses of myocardial collagen deposition, capillary density, and
myocyte size were performed for myocardial structure characterization.
Finally, the upper pole of the left kidney was used for analysis of tubulo-
interstitial (TI) damage. Scored variables were the amount of inflamma-
tory infiltrate between tubuli, interstitial fibrosis, tubular atrophy, and
dilatation. A total TI damage score was calculated by summing the scores
for the four variables. Fat deposition in the liver was also analysed for
liver steatosis.
2.6 Data analysis
Data are presented as mean± SEM. Comparison of variables between
the two groups was performed by unpaired Student’s t-test (StatView
5.0 SAS Institute Inc.). Vasodilator responses to BK and SNAP were ex-
pressed as percentage of the preconstriction to U46619.
Vasoconstrictor responses to U46619 were normalized to 10-1mol/l
KCl. Statistical analysis of CRCs, changes in mean aortic pressure over
time and the measurements of Fpas were performed using two-way
ANOVA and the analysis of the LAP measurements during exercise
using regression analysis. P< 0.05 was considered statistically significant.
3. Results
3.1 Model characteristics
At 6-month follow-up, DMþHCþHT animals had lower body weights
(79±3 kg) than their age-matched controls (102±4 kg, P< 0.05). No sig-
nificant group differences were detected in LV-, left atrial-, or right ven-
tricular weights, when normalized to body weight (see Supplementary
material online, Table S3).
A significant decrease in insulin as well as significant increases in glu-
cose, total cholesterol, LDL-, and HDL-cholesterol values, and the LDL/
HDL ratio and to a lesser extent in triglycerides (P= 0.07), were
observed in DMþHCþHT compared to controls (Table 1). Metabolic
dysregulation was also accompanied by increased mRNA-expression of
pyruvate dehydrogenase lipoamide kinase isozyme 4 (PDK4, a regulator
of glucose metabolism and a marker of diastolic dysfunction15), in
DMþHCþHT as compared to controls (1.91±0.24 vs. 1.00±0.22 AU,
P< 0.05, see Supplementary material online, Table S4), which correlated
with plasma glucose levels (P< 0.05). TNF-a plasma levels were signifi-
cantly higher than those of healthy controls, consistent with a chronic in-
flammatory status in these animals, which correlated with the levels of
glucose (see Supplementary material online, Figure S1A, P< 0.05), but not
with plasma lipids (see Supplementary material online, Figure S1B).
Plasma levels of ASAT were similar between groups (42±11 in
DMþHCþHT vs. 40±2 U/l in Control), but ALAT was significantly
lower in DMþHCþHT as compared to controls (24±4 vs. 51±2 U/l,
P< 0.05), despite a significant increase in fat deposition in the liver of
DMþHCþHT animals (0.86 ± 0.31% vs. 0.03± 0.01%; P< 0.05). These
data are consistent with findings in other pig models of metabolic dys-
function and might be related to the high fructose and high sucrose con-
tent of the diet.16,17
Mean aortic pressure, measured under general anesthesia, rose from
62±3 mmHg immediately prior to injection to 87±4 mmHg following in-
fusion of the polyethylene beads in the kidneys (P< 0.05). The increase
in aortic pressure was well maintained over time, as indicated by the bi-
weekly measurements in the awake state, with animals standing quietly
in their cage (Figure 1A).
Kidneys of the DMþHCþHT animals were smaller than kidneys of
controls; however, when corrected for body weight, these differences
were no longer apparent (see Supplementary material online, Table S3).
Representative histology is shown for control and DMþHCþHT kid-
ney cortex (Figure 1B). Total tubulo-interstitial (TI) damage score
was higher in the DMþHCþHT group (P< 0.001, Figure 1C). The
DMþHCþHT group showed no increase in peritubular infiltrate (data
not shown), but showed more interstitial fibrosis (Figure 1D), a trend to-
wards atrophy (Figure 1E, P= 0.06) and increased dilatation (Figure 1F) of
the tubuli compared to controls. Consequently, GFR, measured by inulin
clearance, was significantly reduced in DMþHCþHT as compared to
healthy controls, indicative of kidney dysfunction (P< 0.05, Table 1).
Although no differences in plasma creatinine or urea values were
observed between the groups, cystatin C levels were significantly higher
in the DMþHCþHT group (P< 0.05). Cystatin C strongly correlated
with the levels of TNF-a (P= 0.005, see Supplementary material online,
Figure S1C). There was a trend towards an increase in plasma aldoster-
one (10.4±4.1 vs. 1.4±0.01 pg/ml, P= 0.06).
3.2 Coronary small artery function
Small arteries from DMþHCþHT showed similar preconstriction
to 10-6M U46619 as control vessels, i.e. 65±6% vs. 70±16% of the re-
sponse to 10-1mol/l KCl in the BK experiments, and 62±8% vs. 64±8%
in the SNAP experiments (both P= NS). The vasorelaxation to the
endothelium-dependent vasodilator BK was significantly blunted in
......................................................................................................
Table 1 Arterial blood characteristics in DMþHCþHT
swine group vs. control, obtained at fasting state under
anesthesia
Parameter Control
(N5 8)
DM1HC1HT
(N5 10)
Metabolic function
Glucose (mmol/l) 6.1 ± 0.7 22.7 ± 0.9*
Insulin (ng/l) 39 ± 14 12 ± 1*
Cholesterol (mmol/l) 2.2 ± 0.1 16.8 ± 3.4*
LDL-cholesterol (mmol/l) 1.1 ± 0.1 14.0 ± 3.2*
HDL-cholesterol (mmol/l) 1.1 ± 0.1 5.1 ± 0.7*
LDL/HDL-Cholesterol 1.1 ± 0.1 2.7 ± 0.4*
Triglycerides (mmol/l) 0.35 ± 0.05 1.16 ± 0.36#
Renal function
Urea (mmol/l) 4.2 ± 0.5 3.8 ± 0.4
Creatinine (mmol/l) 130 ± 6 129 ± 11
Cystatin C (mg/l) 0.42 ± 0.01 0.51 ± 0.03*
Aldosterone (pg/ml) 1.4 ± 0.1 10.2 ± 4.1#
GFRa (ml/min) 202 ± 7 123 ± 12*
Inflammation
TNF-a (pg/ml) 74 ± 24 231 ± 64*
IL-6 (pg/ml) 21 ± 8 67 ± 32
GFR was measured in chronically instrumented swine in the awake state.
LDL, low-density lipoprotein; HDL, high-density lipoprotein; GFR, glomerular
filtration rate; TNF-a, tumor necrosis factor alpha; IL-6, interleukin-6.
aN= 4 DMþHCþHT and 4 Controls.
*P< 0.05,
#P= 0.07, DMþHCþHT vs. Control.
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.. DMþHCþHT (Figure 2A), whereas the vasorelaxation to the
endothelium-independent vasodilator SNAP was maintained (Figure 2B),
indicative of endothelial dysfunction. Interestingly, in isolated small
arteries obtained from five additional DMþHCþHT swine, pretreat-
ment with the ROS scavenger N-2-mercaptopropionyl glycine (MPG)
restored the vasodilator response to bradykinin (see Supplementary ma-
terial online, Figure S2).
3.3 Myocardial ROS measurements
Myocardial production of the NO metabolites NO2
- and NO3
- was signifi-
cantly lower in the DMþHCþHT compared to control suggesting
reduced NO production (Figure 3A). However, neither myocardial cGMP
levels (DMþHCþHT: 5.74± 2.14 pmol/mg protein, control swine:
8.12± 2.16 pmol/mg protein, P= 0.4), nor PDE5 activity (1.03± 0.49 vs.
1.40± 1.04 AU/mg protein, P= 0.6), were significantly altered, resulting in
preserved PKG activity (0.49± 0.01 vs. 0.50± 0.02 AU/mg protein, P= 0.7).
Although total eNOS expression was increased in DMþHCþHT as
compared to control (Figure 3B), this increase was principally due to an in-
crease in eNOS monomer, as the monomer/dimer ratio was markedly
higher than in controls (Figure 3C). In addition, eNOS phosphorylation of
residue Ser1177 was higher (possibly reflecting phosphorylation of the
eNOS monomer18), suggesting that not only eNOS expression but also
eNOS activity was increased (Figure 3D). The increase in monomer/dimer
ratio in DMþHCþHT reflects uncoupling of eNOS. Accordingly, basal
superoxide production was 3-fold higher in DMþHCþHT (Figure 3E)
with the increased superoxide values correlating with inflammation (see
Supplementary material online, Figure S1D) and the decrease in cardiac
NO production (P= 0.008, see Supplementary material online, Figure S1E).
This increase was suppressed by both L-NAME and VAS2870 (both
P< 0.05), indicating that both NOS and NADPH oxidase contributed to
superoxide production (Figure 3E). NADPH resulted in exaggerated—and
VAS2870-inhibitable, but not L-NAME-inhibitable—superoxide produc-
tion in DMþHCþHT as compared to controls (Figure 3F), confirming
NADPH oxidase as a major source of superoxide in DMþHCþHT ani-
mals in addition to the uncoupled NOS-dependent superoxide produc-
tion. NOX2 and 4 expression in the myocardium of DMþHCþHT did
not differ from controls (see Supplementary material online, Table S4), sug-
gesting that enzyme activity rather than transcriptional activation was
higher in these animals. In contrast, gene expression of SOD-1 and catalase
were higher in the DMþHCþHT as compared to controls (SOD-1
1.30± 0.09 vs. 1.00± 0.08, P< 0.05; catalase 2.44± 0.21 vs. 1.00± 0.22 AU,
P< 0.05), likely representing a feedback mechanism to compensate for the
A B
C D
E F
Figure 1 Mean arterial pressure (MAP), measured in resting awake
state, was increased over time in DMþHCþHT as compared to
healthy control swine from our laboratory (unpublished data) per-
formed in the same time period (A). Representative PAS stained sec-
tions of the top part of the left kidney of control and DMþHCþHT
swine at a magnification of 200. Scale bar = 50lm (B). Increased
tubulo-interstitial damage in kidney sections of DMþHCþHT swine
compared to control healthy swine (C). Total tubulo-interstitial damage
score was calculated by summing the scores for peritubular inflamma-
tory infiltrate (not shown), interstitial fibrosis (D), atrophy (E) and dila-
tation (F) (Control N= 8, DMþHCþHT N= 11). *P< 0.05, #P= 0.06.
A B
Figure 2 Concentration response curves to bradykinin (BK, A) and the NO-donor S-nitroso-N-acetylpenicillamine (SNAP, B) in small arteries isolated
from DMþHCþHT and healthy control hearts. *P< 0.05 DMþHCþHT vs. Control by 2-way ANOVA.
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.increased oxidative stress. In accordance with the expression data, myo-
cardial catalase activity was also increased in DMþHCþHT swine as
compared to the healthy controls (22.3± 1.4 vs. 12.1± 0.3 nmol/min/mg
protein, P= 0.0001). Both catalase (P= 0.0007) and SOD-1 (P= 0.02) ex-
pression correlated with superoxide production (see Supplementary ma-
terial online, Figure S1F and G).
3.4 Myocardial structure: collagen content,
myocardial hypertrophy, and capillary
density
The histological findings in the subendocardial layer of the LV anterior
wall of animals from both groups are shown in Figure 4 and summar-
ized in Figure 5. Total collagen deposition (collagen type Iþ III, Figure
4A and D) was assessed in the subendocardial and subepicardial layers
of the LV. Collagen deposition was significantly increased in the suben-
docardium of DMþHCþHT as compared to control swine (Figure
5A), which correlated with the superoxide production (P= 0.0001,
see Supplementary material online, Figure S1H). No difference was
found between the subendocardium and the subepicardium in each
group (data not shown). Moreover, molecular data suggest reduced
matrix turnover in the subendocardium of DMþHCþHT animals,
since expression of both MMP-2 and TIMP-2 was lower, while expres-
sion of MMP-9 and TIMP-1 was unaltered in DMþHCþHT animals
as compared to controls (see Supplementary material online, Table
S4). The MMP-2/TIMP-2 ratio was also significantly lower in the
DMþHCþHT groups compared to control animals (0.72 ± 0.05 vs.
0.89 ± 0.03, P= 0.01), while the ratio MMP-9/TIMP-1 was similar
(1.17 ± 0.21 vs. 1.73 ± 0.51, P= NS).
The measurement of the cardiomyocyte cross-sectional area (Figure
4B and E), revealed that cardiomyocytes from the DMþHCþHT were
significantly smaller than those of control swine, which was observed in
both subendocardium (413±42 lm2 vs. 598±23 lm2, P< 0.05; Figure 5B)
and subepicardium (379±29 lm2 vs. 676±31 lm2, P< 0.05; data not
shown in Figure 5B). Cardiomyocyte size was inversely correlated with
the levels of cystatin C (P= 0.02), a potent risk factor for cardiovascular
disease associated mortality and a strong marker for renal dysfunction.
Interestingly, when normalized to body weight, the difference in myocyte
area between Control and DMþHCþHT was no longer observed.
In line with the observed reduction in cardiomyocyte size in
DMþHCþHT, myocardial ATF4 expression was significantly higher in
the DMþHCþHT as compared to controls (1.51 ± 0.12 vs.
1.00 ± 0.08 AU, P< 0.05), which may suggest increased ER stress in the
cardiomyocytes as a result of the comorbidities. The gene expressions
of ANF/NPPA, UBE2H, and ACTA1 and 2 in the myocardium were not
different between groups (see Supplementary material online, Table S4),
in line with the lack of myocyte hypertrophy in DMþHCþHT.
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(peNOS) was also significantly increased in DMþHCþHT (D) (N= 10) vs. Control (N= 8). Superoxide generation was increased in the LV subendocar-
dium of DMþHCþHT vs. Controls and was suppressed by L-NAME and VAS2870 (E). Upon NADPH oxidase stimulation, the superoxide anion produc-
tion was dramatically increased (F), which was inhibited by VAS2870 but not by L-NAME treatment. *P< 0.05 DMþHCþHT vs. Control; †P< 0.05 vs.
corresponding basal.
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..Capillary density (Figure 4C and F) was similar between the groups
(Figure 5C) and also between the subendocardium and subepicardium in
each group (data not shown). However, the capillary-to-fiber ratio was
significantly lower in DMþHCþHT as compared to controls, suggest-
ive of capillary rarefaction (Figure 5D). No differences were observed be-
tween the subendocardium and subepicardium of either group (not
shown). Unpublished data from our laboratory obtained in weight-
matched DMþHCþHT animals showed no difference in myocyte size
vs. control animals, while showing a significant reduction in capillary
density (1237 ± 81 in DMþHCþHT vs. 1548 ± 88 capillaries/mm2 in
control, P= 0.03).
3.5 Single myocyte force measurements
Increased maximal force (Fmax, Figure 6A) as well as increased passive
stiffness (Fpas, Figure 6B) of the cardiomyocytes isolated from the suben-
docardium of the LV anterior wall was observed in DMþHCþHT
as compared to controls. Myocardial N2BA/N2B titin expression
showed a shift towards the stiff N2B titin isoform (Figure 6C, P= 0.01),
consistent with the increased passive stiffness of the cardiomyocytes,
while no significant change in total phosphorylation of either isoform
was observed (N2BA: 0.76± 0.06 AU in Control vs. 0.74 ± 0.05 AU in
DMþHCþHT; N2B: 0.98 ± 0.11 AU in Control vs. 0.92± 0.07 AU in
DMþHCþHT).
3.6 Cardiac MRI and global LV function
MRI and PV loop variables as well as typical examples of E and A waves
(Figure 6D and E) and pressure–volume loops (preload reduction, Figure
6G) are shown in Table 2 and Figure 6. LV EDV and SV, indexed to body
weight, and ejection fraction were not different between the two groups,
measured by either MRI or PV loop catheter (Table 2). Late gadolinium
enhancement did not show any difference between the groups (data
not shown), despite an increased collagen content in the LV of
DMþHCþHT animals as measured histologically (Figure 5A). However,
E/A ratio tended to be lower in the DMþHCþHT group, suggestive of
early diastolic dysfunction (Figure 6F). These findings were complemented
by the pressure–volume data, showing that DMþHCþHT animals had
increased LV end-diastolic elastance, indicative of increased passive stiff-
ness of the LV in vivo (Figure 6H, P< 0.05). The increase in LV end-diastolic
A
D E F
B C
Figure 4 Examples of histological staining for quantification of collagen deposition (Picrosirius Red A, D), myocyte size (Gomori B, E), and capillary density
(Lectin C, F) in the LV subendocardium in Control (CON), and DMþHCþHT animals.
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elastance correlated with the increased collagen deposition in the suben-
docardium (see Supplementary material online, Figure S1I, P= 0.05).
LV end-systolic elastance also tended to be higher in these animals, al-
though this failed to reach statistical significance (Figure 6I, P= 0.10), which
correlated well with the maximal force development of single cardiomyo-
cytes (P= 0.006). Although no significant group differences were observed
in LV end-diastolic pressure, dP/dtmax, LV dP/dtmin, or tau (Table 2), we did
observe a shift in the relation between left atrial pressure and cardiac index
(Figure 7) in chronically instrumented DMþHCþHT compared to con-
trol swine during exercise (P< 0.05). These data indicate that in swine in
the awake state, at similar levels of cardiac index higher atrial filling pres-
sures were observed in DMþHCþHT compared to control swine.
4. Discussion
In the present study, we report that in the absence of major geomet-
rical alterations in the heart, the co-existence of three common
comorbidities leads to LV diastolic dysfunction as evidenced by
increased passive LV stiffness and a trend towards reduced LV dia-
stolic early-to-late filling velocities, while EF was still preserved. The
cascade of events leading to diastolic dysfunction is summarized in
Figure 8,19 in which the events that were observed in the present
study are highlighted in bold. These include the presence of chronic
systemic inflammation and decreased endothelium-dependent vaso-
dilation in the coronary arteries as assessed in vitro. We also observed
reduced capillary-to-fiber ratio, elevated superoxide production due
to NOX activation, eNOS uncoupling, and reduced myocardial NO
production, all likely to be important mechanisms for the observed
increases in LV collagen content and cardiomyocyte passive force
contributing to LV stiffening and thereby reduced diastolic function.12
Paulus and Tscho¨pe12 proposed that a systemic inflammatory state
produced by cardiovascular comorbidities is common in many HF pa-
tients, particularly those with HFpEF.20,21 The inflammatory state pro-
motes coronary microvascular endothelial dysfunction, which is
characterized by generation of reactive oxygen species and reduced NO
bioavailability, and leads to a cascade of signaling events that ultimately
promotes cardiac fibrosis and myocyte stiffness. Indeed, it is now well es-
tablished that multiple common comorbidities, including obesity, DM,
and HT, are strongly associated with HFpEF.5–7,22–24 This cascade of
events could be faithfully recapitulated in the present study, although the
causality between the various steps remains to be tested. Firstly, a pro-
inflammatory state was documented by markedly elevated levels of cir-
culating TNF-a in diseased animals. TNF-a values correlated with the
levels of glucose and cystatin C, confirming that DM and kidney dysfunc-
tion (as evidenced by high tubulo-interstitial damage score, increased
cystatin C levels, and impaired GFR, despite normal urea and creatinine
levels), are important contributors to increased systemic inflammation.
Secondly, coronary small artery endothelial dysfunction was also evident
as relaxation responses to bradykinin were diminished, while smooth
muscle cell function was preserved as indicated by the preservation of
vascular responses to the exogenous NO donor SNAP and the main-
tained cGMP-PDE5-PKG signaling, although the latter was measured in
the myocardium and might also, partly, reflect cardiomyocyte signaling.
Thirdly, and perhaps most importantly, ROS production was markedly
increased and correlated with the decreased cardiac NO production.
Specifically, the basal superoxide production was increased 3-fold in
DMþHCþHT as compared to control swine. This increase was signifi-
cantly suppressed by L-NAME as well as by VAS2870, indicating that
A B
C D
Figure 5 Increased collagen deposition (A) but no myocyte hypertrophy (B) was recorded in LV subendocardium of the DMþHCþHT animals.
Capillary density was similar between groups (C), however the capillary-to-fiber ratio was significantly reduced in DMþHCþHT (D). *P< 0.05
DMþHCþHT (N= 10) vs. Control (N= 8).
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..both NOS and NADPH oxidase were sources of superoxide produc-
tion. Upon stimulation of NOX, myocardial superoxide production was
markedly increased in DMþHCþHT as compared to controls, con-
firming NOX as the major source of superoxide. This was probably
due to the increase in NOX-activity, as myocardial gene expression was
not significantly different between groups. Furthermore, although
increased eNOS expression and phosphorylation levels were observed
in DMþHCþHT animals, the monomer/dimer ratio was increased al-
most 3-fold, indicating that eNOS-uncoupling accounted for the aggra-
vated NOS-dependent superoxide production. The increased
myocardial superoxide levels in conjunction with low NO levels suggest
direct quenching of NO by superoxide as a major factor contributing to
the reduced NO bioavailability in the present animal model, both basal
and agonist induced. This is in agreement with data from Paolocci et al. in
isolated rat hearts.25 In our model, the increase in superoxide production
correlated with the levels of TNF-a, confirming that inflammation is one
of the important mechanisms leading to the increase in oxidative stress in
the diseased animals. Interestingly, catalase activity, as well as the expres-
sion of catalase and SOD-1 were also significantly increased in the
diseased animals, representing a possible compensatory mechanism for
increased oxidative stress as both expression levels correlated with
superoxide production.
The observed functional alterations were associated with structural
vascular impairments in the myocardium of DMþHCþHT animals.
We observed capillary rarefaction as evidenced by lower capillary-to-
fiber ratio in the diseased hearts. Capillary rarefaction has been asociated
with metabolic syndrome in animal models26 and has only been sparsely
investigated in previous studies of diastolic dysfunction, but our findings
are in accordance with a study by Mohammed et al. who reported a
reduced capillary density in the myocardium of HFpEF patients.27
Capillary rarefaction may have important clinical implications, particu-
larly when occurring simultaneously with the observed coronary arterial
endothelial dysfunction, as it will impair myocardial oxygenation espe-
cially during physical exercise.28 These microvascular alterations, at the
level of both small arteries and capillaries, may contribute to reduced ex-
ercise tolerance in HFpEF patients.29 The observed vascular changes
were accompanied by an increase in total collagen, which together with
the increased passive stiffness of single cardiac myocytes (likely due to
the shift towards the stiffer titin N2B isoform), translated into higher LV
stiffness30–32 as demonstrated by increased LV end-diastolic elastance
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Figure 6 Increased maximal (Fmax, A) and passive force (Fpas, B) were seen in DMþHCþHT as compared to Controls. Cardiomyocyte data were aver-
aged for all measured cells and group averages are shown. Titin N2BA/N2B isoforms ratio was significantly decreased in DMþHCþHT animals
(C). Typical examples of E and A waves in Control (D) and DMþHCþHT (E) animals and pressure–volume relationships (G) are presented. The early to
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Control.
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and the trend towards a decreased E/A ratio, both clear indicators of dia-
stolic dysfunction. Indeed, the increase in collagen correlated with the
increased LV end-diastolic elastance, indicating collagen deposition in the
myocardium as an important determinant of increased stiffness. The acti-
vation of pro-fibrotic pathways in the myocardium and the resulting in-
crease in collagen deposition is likely due to the increased oxidative
stress and inflammation modulating the TGF-beta/SMAD3 signalling
pathway.33 Furthermore, Westermann et al.34 have shown in patients
with HFpEF that cardiac inflammation results in accumulation of extra-
cellular matrix contributing to the development of diastolic dysfunction.
Disturbed turnover of extracellular matrix, mediated through dysregula-
tion of MMPs and their tissue inhibitors (TIMPS) is likely to play a role in
this process. Our data suggest a reduced, rather than increased, matrix
turnover in the myocardium of the animals with comorbidities at this
stage of the disease. In addition, data obtained in a dog model of subacute
heart failure indicate that persistent neurohumoral activation, which is
also likely to be present in our porcine model, may result in high-energy
phosphate depletion and enhancement of AMP deaminase activity con-
tributing to myocardial stiffening irrespective of changes in extracellular
matrix.35 The structural abnormalities observed in the present study
translated into a shift in the relation between left atrial pressure and car-
diac index in exercising swine, indicating that also during exercise higher
filling pressures were required to achieve a similar level of cardiac index,
consistent with a stiffer heart. Interestingly, the increased maximal force
of single cardiomyocytes correlated with the observed trend towards
increased LV end-systolic elastance. It could therefore be speculated
that the increase in contractility acted as a compensatory mechanism to
maintain LV function particularly in the face of the elevated blood pres-
sure in the absence of LV hypertrophy.36
4.1 Aspects of the experimental model
The animal model presented here is complementary to a recently re-
ported porcine model of diastolic dysfunction.37 Schwarzl et al. induced
HT and HC using DOCA-salt and western diet containing high amounts
of salt, fat, and cholesterol. An important difference between the two
studies, besides the longer follow-up in our study (6 months vs.
12 weeks), was the induction of diabetes and kidney dysfunction in our
model. The type of diabetes induced in our study is not consistent with
either DM type I or with early DM type II, but rather with a late stage
DM type II with impaired insulin production. In addition, the animals with
comorbidities had a lower body weight, despite increased lipid plasma
levels which may be due to growth retardation, which has also been
shown in children with chronic kidney disease.38 Although Schwarzl
et al.37 reported several similar functional findings, including increased LV
end-diastolic stiffness, increased superoxide production, and eNOS
uncoupling, some findings are distinctly different. Diabetes, which is a
common comorbidity in HFpEF patients, likely contributed to the endo-
thelial dysfunction and activation of NOX, which are also observed
in HFpEF patients.18 Moreover, whereas concentric LV hypertrophy
occurred in response to the pressure-overload in the study of Schwarzl
et al. cardiomyocyte area was reduced in our model, indicating that in
the present model, myocyte hypertrophy is not a factor contributing to
myocardial stiffening. The lack of myocyte hypertrophy, is in agreement
with the maintained PKG activity levels in our animals and in accordance
with the concept that severe hyperglycemia induces muscle cell atrophy
both in skeletal39,40 and cardiac muscle.41,42 Furthermore, myocyte size
inversely correlated in our animals with the levels of cystatin C suggest-
ing a role of the chronic kidney dysfunction in this process. Schwarzl
et al. only evaluated renal function by creatinine and urea, but not inulin
clearance and cystatin C. Our study shows that marked reductions in
......................................................................................................
Table 2 LV function in control and DMþHCþHT swine
under anesthesia
Parameter Control DM1HC1HT
Body weight (kg) 102 ± 4 79 ± 3*
Pressure-volume catheter N=8 N=10
Heart rate (bpm) 85 ± 3 91 ± 5
LV EDV (ml) 174 ± 22 113 ± 11*
LV EDVi (ml/kg) 1.5 ± 0.2 1.5 ± 0.2
SV (ml) 75 ± 3 55 ± 4*
SVi (ml/kg) 0.75 ± 0.03 0.74 ± 0.08
Ejection fraction (%) 47 ± 5 50 ± 3
Millar catheter N=8 N=10
Heart rate (bpm) 88 ± 4 85 ± 3
dP/dt max (mmHg/s) 1470 ± 138 1604 ± 214
dP/dt min (mmHg/s) -2510 ± 322 -2687 ± 266
Tau (ms) 49 ± 3 48 ± 3
LV EDP (mmHg) 9 ± 2 9 ± 2
MRI N=6 N=7
Heart rate (bpm) 89 ± 7 71 ± 3*
LV EDV (ml) 189 ± 12 162 ± 11
LV EDVi (ml/kg) 1.8 ± 0.1 2.1 ± 0.1
SV (ml) 98 ± 9 73 ± 7*
SVi (ml/kg) 0.93 ± 0.07 0.94 ± 0.06
Ejection fraction (%) 51 ± 3 45 ± 4
LV, left ventricle; SV, stroke volume; EDV, end-diastolic volume; EDVi, end-dia-
stolic volume indexed for body weight; ESV, end-systolic volume; ESVi, end-sys-
tolic volume indexed for body weight; dP/dt min and dP/dt max, minimum and
maximum rate of pressure change in the left ventricle; LV EDP, left ventriclular
end diastolic pressure; Tau, time constant of isovolumic relaxation.
*P< 0.05 compared to Control.
Figure 7 Relation between left atrial pressure (LAP) and cardiac
index (CI) at rest and during treadmill exercise in chronically instru-
mented Control (N= 4; 97± 6 kg, white circles) and DMþHCþHT
(N= 4; 94± 7 kg, black circles) swine. *P< 0.05 DMþHCþHT vs.
Control.
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..glomerular filtration rate are not detected by urea and creatinine in
hypertensive swine. Increased LV fibrosis was documented in the pre-
sent study and correlated with the increased diastolic elastance, but was
not observed in the study by Schwarzl et al., most likely because hyper-
glycemia in addition to inflammation is an important trigger for extracel-
lular matrix remodeling in HFpEF.43,44 Diabetes is known to lead to
vascular deficiency, mediated by miR-320 according to a recent study45
as documented here as capillary rarefaction. In the study by Schwarzl
et al.37 reduced phosphorylation of titin, the giant molecular ‘spring’ that
is considered as one of the most important factors responsible for cardi-
omyocyte passive stiffness, was observed and a shift towards its stiffer
isoform N2B was reported, supporting the concept that both collagen
and titin contribute to myocardial stiffness in HFpEF patients.30 In the
present model, while the shift in titin isoform towards the stiff N2B iso-
form was also documented, a change in total phosphorylation was not
observed. Altogether, data from both models suggest that the presence
of different comorbidities may initiate partially different pathologic path-
ways, that may provide potential targets for further study and mechanis-
tic interventions. Based on the data from the present animal model,
chronic treatment with antioxidants aiming at increasing NO bioavailabil-
ity and alleviating oxidative stress, lowering inflammation, as well as sGC
stimulators might result in reduction of collagen deposition, cardiomyo-
cyte stiffening, and delay of onset of diastolic dysfunction.
4.2 Conclusions
As summarized in Figure 8, the present study demonstrates that in a large
animal, chronic exposure to multiple common comorbidities results in
systemic inflammation, endothelium-dependent coronary microvascular
dysfunction, capillary rarefaction, oxidative stress, and perturbed nitric
oxide production, which are associated with increased myocardial fibro-
sis and passive cardiomyocyte stiffness in the absence of myocyte hyper-
trophy, resulting in LV diastolic dysfunction. Future studies are needed
to address the exact mechanisms connecting the different steps in the
process; however, this large animal model provides an excellent transla-
tional tool for improving our understanding of the early pathophysiology
of heart failure with preserved ejection fraction and for testing novel
therapeutic interventions, including drugs, exercise, and diet interven-
tions, for the treatment of the patients with this type of heart failure.
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Supplementary material is available at Cardiovascular Research online.
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